Oxford Biomedica Share News (OXB)

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

----------

FTSE 100

----------

Exane BNP raises Antofagasta price target to 1,210 (1,190) pence - 'underperform'

----------

Exane BNP raises Rio Tinto to 'outperform' - price target 6,500 pence

----------

Barclays cuts Anglo American price target to 2,865 (2,900) pence - 'overweight'

----------

Goldman Sachs raises Segro price target to 680 (580) pence - 'sell'

----------

Goldman Sachs raises Land Securities to 'buy' (neutral) - price target 690 (580) pence

----------

JPMorgan cuts Hikma price target to 2,200 (2,350) pence - 'overweight'

----------

JPMorgan raises GSK price target to 1,450 (1,400) pence - 'underweight'

----------

JPMorgan cuts AstraZeneca price target to 13,000 (14,000) pence - 'overweight'

----------

Jefferies cuts Compass price target to 2,410 (2,575) pence - 'buy'

----------

Jefferies cuts Entain price target to 890 (915) pence - 'hold'

----------

FTSE 250

----------

Goldman Sachs raises Big Yellow price target to 1,350 (1,280) pence - 'buy'

----------

Goldman Sachs raises Tritax Big Box price target to 180 (160) pence - 'buy'

----------

Goldman Sachs raises Great Portland price target to 380 (360) pence - 'neutral'

----------

Goldman Sachs raises Derwent London price target to 2,319 (2,076) pence - 'buy'

----------

Goldman Sachs raises Supermarket Income REIT price target to 90 (85) pence - 'buy'

----------

Goldman Sachs raises Hammerson price target to 15 (12) pence - 'sell'

----------

Goldman Sachs raises British Land to 'neutral' (sell) - price target 350 (290) pence

----------

RBC cuts Dr Martens price target to 100 (150) pence - 'sector perform'

----------

Barclays cuts Auction Technology to 'equal weight' (overweight) - price target 600 (880) pence

----------

SMALL CAP, AIM and OTHER MAIN MARKET

----------

Goldman Sachs cuts ITM Power price target to 52 (57) pence - 'sell'

----------

JPMorgan cuts Oxford Nanopore price target to 325 (390) pence - 'overweight'

----------

JPMorgan cuts Oxford BioMedica price target to 210 (325) pence - 'neutral'

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.